KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial.

Zijing Liang, Si Liu, Wei Guo, Zhe Deng, Wenkai Bin, Anyong Yu, Junyan Hu, Lidong Wu, Zhanfei Li, Wei Huang, He Li, Dapeng Cheng, Shugui Li, Qinghao Guo, Dongshan Zhang, Xinming Yan, Chunlei Wang, Wenwei Cai, Banghan Ding, Wenqiang Li, Xu Li, Bin Xu, Lei He, Yanhong Ouyang, Hong Zhan, Jianwei Wang, Yan Zhao, Xinyu Liu, Wenxi Xiang, Meizhuo Zhang, Zhihua Zhang, Jiyuan Ding, Xiaohu Kuang, Weihong Zheng, Huaxin Liao, Wanmei Wang, Chuanlin Wang

Nat Med 31(8) 2673-2681

PMID40628965
PMCIDPMC12353795
DOI10.1038/s41591-025-03791-8
发表日期2025-07-08
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:AI 判定为 other;Extended Data Fig. 2:AI 判定为 other。
摘要

摘要

Tetanus remains an important global public health concern. Currently, the only recommended passive immunization therapy for tetanus prophylaxis is plasma-derived human tetanus immunoglobulin (HTIG), which faces a global supply shortage and can transmit infectious pathogens. Despite not being endorsed by WHO due to safety concerns, equine tetanus antitoxin remains widely used in some countries. We conducted a randomized, double-blind, phase 3 trial to evaluate siltartoxatug-a first-in-class recombinant monoclonal antibody-for tetanus postexposure prophylaxis. Participants (n = 675) were randomized (2:1) to receive a single intramuscular injection of siltartoxatug 10 mg or HTIG 250 IU. The study met its primary outcome, with siltartoxatug demonstrating superiority to HTIG in the proportion of participants with an increase of anti-tetanus neutralizing antibody titers from baseline (ΔTiter) ≥ 0.01 IU ml-1 (95.4% versus 53.2%; intergroup difference 42.3% (95% confidence interval, 35.5-49.1; P < 0.0001)). The safety profiles were comparable, with similar incidence of adverse events between the siltartoxatug (38.2%, 168 of 440) and HTIG (33.9%, 75 of 221) groups. These findings highlight siltartoxatug as an effective and safe option for passive immunization against tetanus. ClinicalTrials.gov registration: NCT05664750 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. CONSORT flow diagram. The full analysis set included all randomized participants who received the study drug. The safety set included all treated participants with at least one postadministration safety evaluation. The full analysis set was used for efficacy analysis. The safety set was used for safety analysis.
非 KM Figure
Fig. 2Fig. 2. Anti-tetanus neutralizing antibody ΔTiter–time profiles. a , b , Anti-tetanus neutralizing antibody ΔTiter–time profiles are presented for the overall population ( n = 393 for siltartoxatug, n = 197 for HTIG), with the y axis plotted using a linear ( a ) and a logarithmic ( b ) scale. c , d , Similarly, profiles for participants with baseline antibody titer <0.01 IU ml −1 ( n = 263 for siltartoxatug, n = 122 for HTIG) are shown using a linear ( c ) and a logarithmic ( d ) scale. All participants included in the analysis had not received the tetanus vaccine concomitantly by the corresponding timepoints. The dotted line at 0.01 IU ml −1 represents the protective antibody threshold. The dashed line and dash-dotted line represent the lower limits of quantification for the bioanalytical methods used for HTIG (0.00453 IU ml −1 ) and siltartoxatug (0.005 IU ml −1 ), respectively. ΔTiter values are presented as the geometric mean; error bars, 95% CI.
非 KM Figure
Fig. 3Fig. 3. Anti-tetanus antibody titers–time profiles in the siltartoxatug + vaccine and HTIG + vaccine subgroups. a , b , Anti-tetanus antibody titers–time profiles are shown for the subgroups of participants who concomitantly received the tetanus vaccine ( n = 47 for siltartoxatug, n = 24 for HTIG), with the y axis plotted using a linear ( a ) and a logarithmic ( b ) scale. c , d , Similarly, profiles for participants with baseline antibody titer <0.01 IU ml −1 in the subgroups ( n = 28 for siltartoxatug, n = 14 for HTIG) are displayed on a linear ( c ) and a logarithmic ( d ) scale. Anti-tetanus antibody (polyclonal antibody) titers were measured using the HTIG PD bioanalytical method for both subgroups. The dashed line indicates the lower limit of quantification for the bioanalytical method (0.00453 IU ml −1 ). Titers are presented as the geometric mean; error bars, 95% CI.
非 KM Figure
Extended Data Fig. 1Extended Data Fig. 1. Anti-tetanus neutralizing antibody ΔTiters-time profiles of siltartoxatug by ADA status. The anti-tetanus neutralizing antibody ΔTiters-time profiles for the siltartoxatug group are shown for ADA positive participants (n = 58) and ADA negative participants (n = 379), with the y-axis presented on a linear scale ( a1 ) and a logarithmic scale ( a2 ). Similarly, profiles for participants with baseline antibody titer <0.01 IU/mL in the siltartoxatug group (n = 228) and HTIG group (n = 33) are displayed on a linear scale ( b1 ) and a logarithmic scale ( b2 ). All participants included in the analysis received siltartoxatug and had evaluable ADA results. Antibody titers were measured using the TNM002 PD bioanalytical method. The dotted line at 0.01 IU/mL indicates the protective antibody threshold, while the dashed line indicates the lower limit of quantification for the bioanalytical method used for siltartoxatug (0.005 IU/mL). The ΔTiters are presented as the geometric mean ± 95% CI, with error bars indicating the 95% CI.
非 KM Figure
Extended Data Fig. 2Extended Data Fig. 2. Pharmacokinetic concentration-time profiles by ADA positive and negative (pharmacokinetic set). The siltartoxatug serum concentration-time profiles was presented by ADA-positive (n = 58) and ADA-negative (n = 378) participants, with y-axis plotted using a linear scale ( a ) and a logarithmic scale ( b ). Participants included in the analysis were those who received siltartoxatug and had at least 1 available post-administration data for pharmacokinetics. Data are presented as arithmetic mean ± arithmetic standard deviation. The dashed line indicates the lower limit of quantification for the bioanalytical method for measuring the siltartoxatug concentration (20 ng/mL).
非 KM Figure